Placeholder

Push for Transparency Creates New Environment for KOLs

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1517. Category: .

Product Description

While the debate on the ethics and value of key opinion leaders (KOLs) rages on inside and outside the industry, our experts tell us that the role of KOLs will not soon disappear and that the call for added transparency is a positive change.
The drive for more transparency is expected to further clarify the KOL role. And as physician relationships are disclosed, thought leaders will be held more accountable for their actions, resulting in a higher quality of work and level of knowledge.
“The use of key opinion leaders has become a more thoughtful and more deliberate process,” says Michael Curry, president of Curry Rockefeller Group. “Increasingly, physician interactions require disclosure and these engagements must be justified to senior management, which elicits a much more rigorous discussion of who exactly is needed and what his or her role should be. In the end, there may be fewer interactions, but the ones that do take place will be ones of greater depth.”

Sidebars:
KOL Transparency in the News
Is Pfizer’s new CME funding policy affecting KOLs?

Experts on this topic

Archibald Anderson. VP, Strategy, Partner, ROI2, a subsidiary of ProLink Services, which offers a next-generation business intelligence platform, Influence Intelligence, to pharmaceutical and biopharmaceutical companies. For more information, visit roi2.com.
Michael Curry. President, Curry Rockefeller Group, an independent,full-service, medical education agency delivering thought leader-focused medical education and publication planning and applied digital science initiatives. For more information, visit curryrockefellergroup.com.
Leo Francis, Ph.D. President, Publicis Medical Education Group (PMEG), which is part of Publicis Healthcare Communications Group, one of the largest healthcare communications groups in the world. For more information, visit publicishealthcare.com.
Scott Mader. President and CEO,
Clindevor360, a consulting organization that provides services for strategic business planning and clinical market development. For more information, visit clindevor.com.
Rob Nauman. Principal, BioPharma Advisor Network, a community of experienced pharmaceutical
professionals working together to solve key business issues and create organizational changes that maximize revenue and minimize cost. For more information, visit biopharmaadvisors.net.

FEEDBACK